These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36579028)

  • 1. Cancer immune profiling unveils biomarkers, immunological pathways, and cell type score associated with glioblastoma patients' survival.
    Moreno DA; da Silva LS; Gomes I; Leal LF; Berardinelli GN; Gonçalves GM; Pereira CA; Santana IVV; Matsushita MM; Bhat K; Lawler S; Reis RM
    Ther Adv Med Oncol; 2022; 14():17588359221127678. PubMed ID: 36579028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.
    Liu YQ; Wu F; Li JJ; Li YF; Liu X; Wang Z; Chai RC
    Front Oncol; 2019; 9():1433. PubMed ID: 31921684
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic-related gene pairs signature analysis identifies ABCA1 expression levels on tumor-associated macrophages as a prognostic biomarker in primary IDH
    Wang S; Li L; Zuo S; Kong L; Wei J; Dong J
    Front Immunol; 2022; 13():869061. PubMed ID: 36248907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients.
    Ye N; Jiang N; Feng C; Wang F; Zhang H; Bai HX; Yang L; Su Y; Huang C; Wanggou S; Li X
    J Cancer; 2019; 10(22):5536-5548. PubMed ID: 31632497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting copper death genotyping associated gene RARRES2 suppresses glioblastoma progression and macrophages infiltration.
    Yan T; Yang H; Meng Y; Li H; Jiang Q; Liu J; Xu C; Xue Y; Xu J; Song Y; Chu X; Wang L; Chen X; Che F
    Cancer Cell Int; 2023 May; 23(1):105. PubMed ID: 37246211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma.
    Sun Z; Zhao Y; Wei Y; Ding X; Tan C; Wang C
    Front Immunol; 2022; 13():939523. PubMed ID: 36091049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling.
    Long S; Li M; Liu J; Yang Y; Li G
    Aging (Albany NY); 2020 Apr; 12(8):7112-7128. PubMed ID: 32310827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
    Burgenske DM; Yang J; Decker PA; Kollmeyer TM; Kosel ML; Mladek AC; Caron AA; Vaubel RA; Gupta SK; Kitange GJ; Sicotte H; Youland RS; Remonde D; Voss JS; Fritcher EGB; Kolsky KL; Ida CM; Meyer FB; Lachance DH; Parney IJ; Kipp BR; Giannini C; Sulman EP; Jenkins RB; Eckel-Passow JE; Sarkaria JN
    Neuro Oncol; 2019 Nov; 21(11):1458-1469. PubMed ID: 31346613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.
    Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
    J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy.
    Schoedel K; Heim T; Duensing A; Lohse I; Presutti L; Belayneh R; Bhogal S; Singh-Varma A; Chang A; Chandran U; Marker D; Szabo-Rogers H; Weiss K
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma.
    Bi Y; Wu ZH; Cao F
    BMC Cancer; 2022 Mar; 22(1):233. PubMed ID: 35241019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A necroptosis-related lncRNA signature was identified to predict the prognosis and immune microenvironment of IDH-wild-type GBM.
    Song C; Zhu L; Gu J; Wang T; Shi L; Li C; Chen L; Xie S; Lu Y
    Front Oncol; 2022; 12():1024208. PubMed ID: 36601479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
    Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
    Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
    Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
    J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.